Meiji Seika Pharma launches two-dose vial of KOSTAIVE (sa-mRNA COVID-19 vaccine) in Japan

Arcturus Therapeutics Holdings Inc.

New two-dose vial presentation of KOSTAIVE launched in Japan on September 26, 2025.
Vaccine targets SARS-CoV-2 Omicron sublineage JN.1 variant XEC.
Non-clinical studies show neutralizing antibodies against XEC, LP.8.1, XFG, NB.1.8.1 variants.
Manufacturing and marketing approval granted August 28, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.